Is a Form 483 the same as a Warning Letter?

No. A Form 483 lists an FDA investigator’s observations at the close of an inspection; it is not a final agency determination. FDA may or may not follow up with a Warning Letter depending on the firm’s response and the severity of the findings.

Where can I read the full Form 483?

The verbatim inspection record is the source of truth — always confirm citation language against the original FDA document before acting.

What is an FDA Form 483?

A Form FDA 483 lists an FDA investigator’s written observations at the close of a facility inspection, issued under section 704(b) of the Federal Food, Drug, and Cosmetic Act. It documents conditions the investigator judged may violate FDA regulations. A 483 is not an enforcement action or a final determination that a violation occurred.

Does this Form 483 mean Turbare Manufacturing violated the law?

No. A Form 483 documents an investigator's observations only. FDA reviews the firm's written response and any corrective actions taken before deciding whether further action is warranted, and many 483s are closed without additional enforcement once a firm shows adequate correction.

FDA Form 483 — Turbare Manufacturing (July 7, 2026)

Key facts

Firm	Turbare Manufacturing
FEI / inspection ID	3027507354
Inspection end date	July 7, 2026
Citation count	4

Key takeaway: FDA inspected Turbare Manufacturing in Arkansas and issued a Form 483 listing 4 inspectional observations following an inspection that concluded 2026-07-07. FDA records classify Turbare Manufacturing as a outsourcing facility. A Form 483 documents an investigator's findings at the close of an inspection under the Federal Food, Drug, and Cosmetic Act; it is not a final agency compliance determination. The observations on this page are drawn directly from the FDA-issued Form 483 record. A Form FDA 483 is issued at the close of an FDA facility inspection to list conditions an investigator observed that may violate the Federal Food, Drug, and Cosmetic Act or its implementing regulations. It reflects the investigator's professional judgment at that point in time and is not a final agency determination, an enforcement action, or proof that a violation occurred. Firms are expected to respond in writing, typically within 15 business days, describing the corrective and preventive actions they plan to take. FDA reviews that response, along with any follow-up evidence, before deciding what happens next. Many 483s are resolved through corrective action alone. When FDA judges a firm's response inadequate, or when the underlying conditions are serious enough, the observations documented here can lead to a Warning Letter or further regulatory action. This page presents the observations exactly as recorded on the FDA-issued document; always confirm citation language against the original record before relying on it.

What a Form 483 means

A Form FDA 483 is issued at the close of an FDA facility inspection to list conditions an investigator observed that may violate the Federal Food, Drug, and Cosmetic Act or its implementing regulations. It reflects the investigator's professional judgment at that point in time and is not a final agency determination, an enforcement action, or proof that a violation occurred. Firms are expected to respond in writing, typically within 15 business days, describing the corrective and preventive actions they plan to take. FDA reviews that response, along with any follow-up evidence, before deciding what happens next. Many 483s are resolved through corrective action alone. When FDA judges a firm's response inadequate, or when the underlying conditions are serious enough, the observations documented here can lead to a Warning Letter or further regulatory action. This page presents the observations exactly as recorded on the FDA-issued document; always confirm citation language against the original record before relying on it.

Citations explained

Observation 1 — The responsibilities and procedures applicable ro the quality control unit are not fully

The responsibilities and procedures applicable ro the quality control unit are not fully followed. Specifically, lA. Your Quality Unit failed to: a.Ensure the timely implementation of corrective and preventive actions for the observed dried and cracked :{6)[4) l 1111 settle plates used for environmental monitoring and then incubated in a 4 fbX ! incubator. Please refer to OBSERVAT IO I. b.Conduct adequate root-cause analyses for the ongoing Envi ronmental Monitoring (EM) and Personnel Monitoring (PM) excursions. The Qua lity unit also failed to perform effectiveness checks on the implemented corrective and preventive actions. as evident by persistent fungal and bacterial recoveries despite implementing corrective actions in the clean room areas. Please refer to OBSERVATlON 2 and

Observation 3 — . c.Investigate the root cause of visual inspec cio n failure during initial 100%

. c.Investigate the root cause of visual inspec cio n failure during initial 100% inspection before proceeding to secondary/tertiary inspection of the fi lled syringes. Please refer to

Observation 4 — . ct .Evaluate air flow patterns under dynamic conditio ns in all ISO 5 classified BSC

. ct .Evaluate air flow patterns under dynamic conditio ns in all ISO 5 classified BSC cabinets in the clean room. Please ref er to OBSERVA TTON 3. AMENDMENT 1 Et,40LOYE£ SIS G•.,-.n,,~ oi:.1e 1ssueo SEE REVERSE Sangee:a ~ Kh ~ ra~ a , I:.v 5- _ g ,:a :_..., ;::: - -- ·.:-=.; I ;; - 2" -c OF THIS PAGE ti/0.i i i1j,_- - ~1 ~-- 1 l ·J ( I,: (e.rc) I X ~l~k FOR\l FO.\. .asJ ({l'Q OS1 ,.., ...,.. .~ ' ?AG!- I ofll PAGES 11 I '\Iii ..• (.! . l\ ~PF( TIO\ \I. 0 8~ ER\ \ TIO\S -- 1 of 14 -- DF:P \RT\IE\ T OF 11£ .\1. r11 \ ,o Ill \I\, ,rR\ I( ES FOOi) \'DORI l, \:)\•t, 1 ,1R \TIO, 12Jl Ma~n Street , S~i:e •20 Dalla s, ~X 75202 (214)253 - 52~C Fax : 2:~ 253 - 53:~ Lacra ~ar ~n , CEO F ~MNA~AE STREET AO0RESS Turba ~e Man~~actJ~i~g CITY S COU NT RY Conwa y , AR 7 2032 - 6E5: lB. Your firm's quality unit failed to ensure the timely implementation of corrective and preventive actions for dried and cracked b 4 media settle plates. The firm uses these b)(4) plates for environmental monitoring in clean room areas as settle plates. After the plates are exposed for b 4 , the plates are collected and incubated at b)(4 ) in incubator# b)(4 ) Upon removal from (b) 4 ) incubator some of these plates ar

Observation 4 — There is a failure to thoroughly review any unexplained discrepancy and the failure of a

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed. Specifica ll y, Your firm failed to conduct, or document, an investigation into the root cause of visual inspection failures prior to proceeding with secondary and/or tertiary inspections. A review of ophthalm ic lot visual inspection records spanning from March 2025 through early 2026 identified forty-fou r (44) lots in which the firm proceeded directly to secondary inspection following a primary visual inspection failure which was characterized by major reject rates exceeding the (6)(4 acceptance l im it and/or major defects found at the primary AQL stage. There was no documented investigation and root cause analysis into the source and cause of these recurring defect types prior to reinspection. In addition i'J◄l ots b)(4) ■ proceeded to tertiary inspection after secondary inspection also fai led, again without a documented investigation. The predominant defect types identified were intr in sic particulate and product fill volume defects. AMENDMENTl EJ·.tP!.OYEE{S) Sa'.:;!l

Turbare Manufacturing’s FDA history

Argus HQ has recorded 1 total FDA action tied to Turbare Manufacturing: 0 warning letters, 0 recalls, 0 approval records, and 1 Form 483 inspection citation.

Frequently asked questions

Is a Form 483 the same as a Warning Letter?: No. A Form 483 lists an FDA investigator’s observations at the close of an inspection; it is not a final agency determination. FDA may or may not follow up with a Warning Letter depending on the firm’s response and the severity of the findings.
Where can I read the full Form 483?: The verbatim inspection record is the source of truth — always confirm citation language against the original FDA document before acting.
What is an FDA Form 483?: A Form FDA 483 lists an FDA investigator’s written observations at the close of a facility inspection, issued under section 704(b) of the Federal Food, Drug, and Cosmetic Act. It documents conditions the investigator judged may violate FDA regulations. A 483 is not an enforcement action or a final determination that a violation occurred.
Does this Form 483 mean Turbare Manufacturing violated the law?: No. A Form 483 documents an investigator's observations only. FDA reviews the firm's written response and any corrective actions taken before deciding whether further action is warranted, and many 483s are closed without additional enforcement once a firm shows adequate correction.

See if this 483 escalates to a warning letter — before your auditor asks.

Free weekly briefing tracks every FDA inspection outcome.

Full FDA history for Turbare Manufacturing

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2026). FDA Form 483 — Turbare Manufacturing (July 7, 2026) — 4 Citations. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/483/turbare-manufacturing-3027507354-2026-07-07

MLA

"FDA Form 483 — Turbare Manufacturing (July 7, 2026) — 4 Citations." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/483/turbare-manufacturing-3027507354-2026-07-07.

Chicago

Argus HQ Research. "FDA Form 483 — Turbare Manufacturing (July 7, 2026) — 4 Citations." Digital Empire Holdings LLC. Accessed July 29, 2026. https://argushq.ai/483/turbare-manufacturing-3027507354-2026-07-07.

BibTeX

@misc{argushq_argushq_ai_483_turbare_manufacturing_3027507354_2026_07_07_2026,
  title = {FDA Form 483 — Turbare Manufacturing (July 7, 2026) — 4 Citations},
  author = {{Argus HQ Research}},
  year = {2026},
  publisher = {Digital Empire Holdings LLC},
  url = {https://argushq.ai/483/turbare-manufacturing-3027507354-2026-07-07},
  note = {Accessed: July 29, 2026}
}

Source: FDA.gov — Inspection Classification Database ↗